本文關(guān)鍵詞：芪黃保腎顆粒對(duì)腎衰竭幼鼠腎小管上皮細(xì)胞E-cadherin表達(dá)的影響　出處：《黑龍江省中醫(yī)藥科學(xué)院》2016年碩士論文　論文類(lèi)型：學(xué)位論文

  更多相關(guān)文章： 芪黃保腎顆粒 腎衰竭 UU OE-cadherin

【摘要】：目的:通過(guò)實(shí)驗(yàn)研究觀察芪黃保腎顆粒對(duì)單側(cè)輸尿管結(jié)扎術(shù)導(dǎo)致腎衰竭幼鼠腎小管上皮細(xì)胞E-cadherin的表達(dá),旨在探討芪黃保腎顆粒在延緩兒童腎衰竭中的作用機(jī)理。方法:將75只體重80-120g,4周齡的SD雄性幼鼠隨機(jī)分為5組:假手術(shù)組、模型組、芪黃保腎顆粒低、中、高劑量組(簡(jiǎn)稱(chēng)低、中、高劑量組),采用單側(cè)輸尿管結(jié)扎(UUO)法建立腎衰竭幼鼠模型,術(shù)前一天12h禁食,飲水自由,術(shù)后即開(kāi)始給藥灌胃。假手術(shù)組、模型組僅給予蒸餾水進(jìn)行灌胃,低、中、高劑量組分別按人與動(dòng)物等效劑量換算法,給予幼鼠芪黃保腎顆粒的用藥劑量分別是2g/kg/d、4g/kg/d、6g/kg/d進(jìn)行灌胃,一次1ml,每日早8:00到晚18:00兩次灌胃,連續(xù)21天。在造模后的第21天選擇每組15只幼鼠收集血液,尿液及腎臟組織后處死,每只幼鼠采取24h留尿及腹主動(dòng)脈采血法,每次采血2-3ml,檢測(cè)血肌酐(Scr)、血清尿素氮(BUN)、血清白蛋白(AIb)及24尿蛋白定量(24Pr),采血后迅速摘下梗阻側(cè)腎臟,觀察其外觀,剝?nèi)ネ饽?生理鹽水沖洗干凈后,將腎臟組織浸于9%福爾馬林藥液中充分固化。通過(guò)模型幼鼠腎組織HE染色、免疫組化法觀察腎臟病理形態(tài)學(xué)的變化以檢測(cè)造模是否成功,同時(shí)以檢測(cè)腎組織中E-cadherin的含量,觀察芪黃保腎顆粒對(duì)E-cadherin表達(dá)的影響,用以確定芪黃保腎顆粒是否通過(guò)抑制E-cadherin的黏附過(guò)程實(shí)現(xiàn)延緩TEC損傷進(jìn)展的。結(jié)果:1.與模型組相比較,芪黃保腎顆粒各劑量組幼鼠梗阻側(cè)腎臟腫大、積水均較輕,幼鼠一般狀態(tài)較好,腎衰癥狀及體征優(yōu)于模型組。2.與模型組相比較,芪黃保腎顆粒各劑量組幼鼠的Scr、BUN均低于模型組(P0.05),芪黃保腎顆粒中劑量組幼鼠Scr、BUN水平最低,而中劑量組與高劑量組Scr、BUN水平相當(dāng),組間比較沒(méi)有統(tǒng)計(jì)學(xué)意義(P0.05)。同時(shí)芪黃保腎顆粒組可以提高腎衰幼鼠AIb。3.與模型組比較,免疫組化半定量分析顯示腎小管上皮細(xì)胞E-cadherin的表達(dá)均高于模型組。其中芪黃保腎顆粒中劑量組幼鼠腎小管上皮細(xì)胞E-cadherin表達(dá)最高(P0.05)。結(jié)論:1.芪黃保腎顆粒能明顯改善腎衰竭幼鼠的腎臟病理?yè)p害,調(diào)整機(jī)體整體情況,緩解腎衰竭幼鼠的癥狀,同時(shí)延緩腎功能的進(jìn)展。2.芪黃保腎顆粒能夠上調(diào)腎衰幼鼠腎臟組織E-cadherin的表達(dá),減少腎小管基底膜的破壞,使細(xì)胞外基質(zhì)成分合成減少,從而抑制腎間質(zhì)纖維化的發(fā)展。3.芪黃保腎顆粒各劑量組在一定程度上均能保護(hù)腎衰幼鼠的腎功能,降低腎小管的損害和拮抗腎間質(zhì)纖維化的發(fā)生,其中芪黃保腎顆粒中劑量的效果最佳,為治療兒童腎衰竭提供了臨床依據(jù)。
[Abstract]:Objective: to observe the expression of E-cadherin in renal tubular epithelial cells of rats with renal failure induced by unilateral ureteral ligation. Objective: to investigate the mechanism of Qihuang Baoshen granule in delaying children renal failure. Methods: 75 male SD rats weighing 80-120g / 4 weeks were randomly divided into five groups: sham operation group and model group. Qi Huang Bao Shen granule is low, medium, high dose group (referred to as low, medium, high dose group), using UUO method of unilateral ureteral ligation to establish the model of kidney failure young rats, fasting 12 hours before operation, drinking water freedom. The model group was only given distilled water, the low, middle and high dose groups were converted according to the equivalent dose of human and animal. The dosage of Qihuangbaoshen granule was 2 g / kg / d 4 g / kg / d and 6 g / kg / d respectively. From 8:00 to 18:00, the rats were given orally twice daily for 21 days. 15 young rats in each group were selected to collect blood, urine and kidney tissue and were killed after 21 days. Blood samples were collected from 24 hours urine and abdominal aorta of each young rat. Blood creatinine (SCR) and serum urea nitrogen (bun) were detected. Serum albumin (AIb) and 24 urinary protein (24) were quickly removed from the obstructed kidney after blood collection, the appearance of the kidney was observed, the outer membrane was peeled off, and the saline was washed out. The kidney tissue was fully solidified in 9% formalin solution. The pathological changes of kidney were observed by HE staining and immunohistochemical method in order to detect the success of the model. At the same time, to detect the content of E-cadherin in renal tissue, to observe the effect of astragalus baoshen granule on E-cadherin expression. To determine whether astragalus baoshen granules can delay the progress of TEC damage by inhibiting the adhesion of E-cadherin. Results: 1. Compared with the model group. Qihuangbaoshen granule of each dose group of young rats obstruction side kidney swelling, hydronephrosis are light, the general state of young rats is better, renal failure symptoms and signs than model group. 2. Compared with model group. 2. The levels of Scr-bun in each dose group of Qihuangbaoshen granules were lower than those of model group (P0.05A), and the level of Scr-bun was the lowest in the middle dose group of Qihuangbaoshen granule. The level of Scrn bun in middle dose group was similar to that in high dose group. There was no significant difference between the two groups (P 0.05). At the same time, Astragalus baoshen granule group could increase the AIb.3. compared with the model group. The expression of E-cadherin in renal tubular epithelial cells was significantly higher than that in the model group, and the E-cadherin table of renal tubular epithelial cells in the middle dose group of Qihuangbaoshen granules was higher than that in the model group. The highest (. Conclusion 1. Astragalus baoshen granule can obviously improve renal pathological damage in young rats with renal failure. Adjust the overall situation of the body, alleviate the symptoms of young rats with renal failure, and delay the progress of renal function. 2. Qihuangbaoshen granule can up-regulate the expression of E-cadherin in kidney tissue of young rats with renal failure. Reduce the destruction of renal tubule basement membrane, reduce the synthesis of extracellular matrix components, so as to inhibit the development of renal interstitial fibrosis .3.Astragalus baoshen granule can protect the renal function of young rats to a certain extent. It can reduce the damage of renal tubules and antagonize the occurrence of renal interstitial fibrosis, of which the middle dose of Qihuangbaoshen granule is the best, which provides the clinical basis for the treatment of children with renal failure.
【學(xué)位授予單位】：黑龍江省中醫(yī)藥科學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類(lèi)號(hào)】：R277.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 夏紅強(qiáng);E-cadherin在腫瘤組織的檢測(cè)及意義[J];臨床腫瘤學(xué)雜志;2003年06期

2 ;Expression of TGF-β1,Snail,E-cadherin and N-cadherin in Gastric Cancer and Its Significance[J];Chinese Journal of Clinical Oncology;2007年06期

3 熊小蔚;崔明;;T-cadherin與腫瘤[J];醫(yī)學(xué)綜述;2010年08期

4 ;E－Cadherin在膀胱乳頭狀移行細(xì)胞癌的表達(dá)[J];國(guó)外醫(yī)學(xué)(生理、病理科學(xué)與臨床分冊(cè));1996年02期

5 張文軍,張志謙,林仲翔,王耐勤,胡穎;Correlation between expression of cadherin and gap junctional communication in human lung carcinoma cells[J];Science in China(Series C:Life Sciences);1998年04期

6 ;The expression of N-cadherin/catenins/actin complex in human lung normal and carcinoma cells[J];Chinese Science Bulletin;1998年09期

7 ;Quantitative analysis of E-cadherin expression and clinicopathologic evaluation in gastric cancer[J];Chinese Medical Journal;1998年01期

8 Ge-Liang Liu;Han-Jie Yang;Tian Liu;Yun-Zhao Lin;;Expression and significance of E-cadherin,N-cadherin,transforming growth factor-β1 and Twist in prostate cancer[J];Asian Pacific Journal of Tropical Medicine;2014年01期

9 王曦,吳人亮,郝天玲,陳芳;Effects of Cigarette Smoke Extract on E-cadherin Expression in Cultured Airway Epithelial Cells[J];Journal of Tongji Medical University;2000年01期

10 陳曉峰,丁嘉安,高文,易祥華,王海峰,李化;E-cadherin表達(dá)與非小細(xì)胞肺癌淋巴結(jié)轉(zhuǎn)移及預(yù)后的相關(guān)性研究[J];中國(guó)肺癌雜志;2002年04期

相關(guān)會(huì)議論文 前10條

1 ;Core Fucosylation Regulates E-cadherin Binding Affinity in Human Lung Cancer Cells[A];2008年全國(guó)生物化學(xué)與分子生物學(xué)學(xué)術(shù)大會(huì)論文摘要[C];2008年

2 ;Epigenetic regulation of E-cadherin in HBV associate human Hepatocellular carcinoma[A];江蘇省遺傳學(xué)會(huì)第八屆會(huì)員代表大會(huì)暨學(xué)術(shù)研討會(huì)論文集[C];2010年

3 王冰晶;張志謙;;癌細(xì)胞cadherin亞型轉(zhuǎn)變及其分子機(jī)制[A];中國(guó)細(xì)胞生物學(xué)學(xué)會(huì)2005年學(xué)術(shù)大會(huì)、青年學(xué)術(shù)研討會(huì)論文摘要集[C];2005年

4 ;Suppressed survival and proliferation of ovarian cancer cells by repressed MEK-ERK activation via knocking-down of E-cadherin[A];中華醫(yī)學(xué)會(huì)腫瘤學(xué)分會(huì)第七屆全國(guó)中青年腫瘤學(xué)術(shù)會(huì)議——中華醫(yī)學(xué)會(huì)腫瘤學(xué)分會(huì)“中華腫瘤 明日之星”大型評(píng)選活動(dòng)暨中青年委員全國(guó)遴選論文匯編[C];2011年

5 ;N-cadherin:a potential receptor of GDNF[A];Proceedings of the 8th Biennial Conference of the Chinese Society for Neuroscience[C];2009年

6 Zhiyang Xu;Dechang Li;Baohua Ji;;Quantification of the stiffness and strength of cadherin ectodomain binding with different ions[A];北京力學(xué)會(huì)第20屆學(xué)術(shù)年會(huì)論文集[C];2014年

7 賈文亮;張慶瑜;;關(guān)于E-cadherin在胃癌和肺癌中表達(dá)情況的研究[A];天津市生物醫(yī)學(xué)工程學(xué)會(huì)第三十三屆學(xué)術(shù)年會(huì)論文集[C];2013年

8 烏新春;倪志超;段昕所;宋有鑫;;綠色熒光蛋白標(biāo)記的T-cadherin基因穩(wěn)定轉(zhuǎn)染黑素瘤細(xì)胞株的建立[A];第五屆全國(guó)中醫(yī)藥免疫學(xué)術(shù)研討會(huì)——暨環(huán)境·免疫與腫瘤防治綜合交叉會(huì)議論文匯編[C];2009年

9 ;Manipulation of N-cadherin level and function through different methods results in distinct functional changes in hippocampal neurons[A];Proceedings of the 7th Biennial Meeting and the 5th Congress of the Chinese Society for Neuroscience[C];2007年

10 張憲真;陳隨芹;耿秀東;;N-Cadherin與E-Cadherin在非小細(xì)胞肺癌中的表達(dá)及相關(guān)性研究[A];中國(guó)腫瘤內(nèi)科進(jìn)展 中國(guó)腫瘤醫(yī)師教育（2014）[C];2014年

相關(guān)博士學(xué)位論文 前10條

1 楊俊俊;Rab5 GTPase介導(dǎo)的VE-cadherin內(nèi)吞調(diào)控肺微血管內(nèi)皮細(xì)胞屏障功能的機(jī)制[D];第三軍醫(yī)大學(xué);2015年

2 黎景佳;E-cadherin在喉鱗狀細(xì)胞癌中的表達(dá)及其與腫瘤侵襲轉(zhuǎn)移的關(guān)系[D];中南大學(xué);2010年

3 吳揚(yáng);VE-cadherin重組腺病毒偶聯(lián)氧化型甘露聚糖抗腫瘤實(shí)驗(yàn)研究[D];四川大學(xué);2005年

4 胡軍;E-cadherin與卵巢癌轉(zhuǎn)移的相關(guān)性及機(jī)制研究[D];大連醫(yī)科大學(xué);2007年

5 來(lái)明名;肌球蛋白X與N-cadherin相互作用調(diào)節(jié)皮層神經(jīng)元輻射遷移[D];東北師范大學(xué);2013年

6 任劍珍;結(jié)腸癌T-cadherin基因的表達(dá)及甲基化影響的探討[D];中南大學(xué);2011年

7 張自森;E-cadherin在胃癌中的表達(dá)與化療療效的關(guān)系及對(duì)胃癌細(xì)胞化療敏感性的影響[D];鄭州大學(xué);2013年

8 余瓊芳;Li-cadherin與結(jié)腸癌LoVo細(xì)胞侵襲轉(zhuǎn)移相關(guān)性實(shí)驗(yàn)研究[D];武漢大學(xué);2009年

9 王博;E-cadherin在急性噪聲損傷中的分子機(jī)制研究[D];中國(guó)人民解放軍醫(yī)學(xué)院;2014年

10 張瑩瑩;乙肝病毒HBx蛋白誘導(dǎo)E-cadherin表觀遺傳沉默促進(jìn)細(xì)胞遷移的機(jī)制研究[D];中國(guó)人民解放軍軍事醫(yī)學(xué)科學(xué)院;2011年

相關(guān)碩士學(xué)位論文 前10條

1 衷燦梅;12-脂氧合酶通過(guò)上皮間質(zhì)轉(zhuǎn)化促進(jìn)胃癌侵襲轉(zhuǎn)移的機(jī)制研究[D];福建醫(yī)科大學(xué);2015年

2 高玉梅;探索N-cadherin在卵巢癌發(fā)生和進(jìn)展中的作用及意義[D];石河子大學(xué);2015年

3 林路;E-cadherin,β-catenin,N-cadherin在漿液性卵巢癌中的表達(dá)及意義[D];安徽醫(yī)科大學(xué);2015年

4 辛明;Galectin-3通過(guò)EGFR介導(dǎo)調(diào)控腫瘤細(xì)胞E-cadherin表達(dá)的機(jī)制研究[D];山東大學(xué);2015年

5 孟梅;VE-cadherin對(duì)血管穩(wěn)態(tài)的作用及調(diào)控機(jī)制[D];蘇州大學(xué);2015年

6 汪威;丙泊酚對(duì)荷瘤大鼠MADB106腫瘤細(xì)胞肺轉(zhuǎn)移及E-cadherin和β-catenin的影響[D];南方醫(yī)科大學(xué);2015年

7 孫琳;ALCAM、E-cadherin和β-catenin在甲狀腺乳頭狀癌中的表達(dá)及意義[D];河北醫(yī)科大學(xué);2014年

8 于海峰;FOXQ1和E-cadherin在食管鱗狀細(xì)胞癌中的表達(dá)及臨床意義[D];天津醫(yī)科大學(xué);2015年

9 何宏月;EMT相關(guān)蛋白E-cadherin、N-cadherin、Snail和Slug在子宮內(nèi)膜異位癥中的表達(dá)及意義[D];天津醫(yī)科大學(xué);2015年

10 劉超;EMX2和E-cadherin在食管鱗癌中的表達(dá)及臨床病理意義[D];天津醫(yī)科大學(xué);2015年

，

本文編號(hào)：1392724